NCT01580241

Brief Summary

The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
16mo left

Started Oct 2010

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Oct 2010Dec 2027

Study Start

First participant enrolled

October 1, 2010

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

April 17, 2012

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 18, 2012

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
12.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Expected
Last Updated

April 1, 2026

Status Verified

March 1, 2026

Enrollment Period

4.8 years

First QC Date

April 17, 2012

Last Update Submit

March 26, 2026

Conditions

Pancreatic Cancer

Study Arms (4)

Surgery group

Patients with pancreatic cancer who undergo surgical treatment only

Chemotherapy group

Patients with pancreatic cancer who undergo chemotherapy treatment only

Neoadjuvant group

Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery

Adjuvant group

Patients with pancreatic cancer who undergo surgery followed by chemotherapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Human patients with pancreatic cancer undergo various treatments for pancreatic cancer. We will examine the expression of Dcamkl-1 pre and post therapy (including, chemotherapy only, surgery only, neoadjuvant and adjuvant therapies) to correlate treatment with a change in DCAMKl-1 expression.

You may qualify if:

  • pancreatic cancer

You may not qualify if:

  • age \< 18, history of other types of cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stephensen Cancer Center

Oklahoma City, Oklahoma, 73104, United States

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • Courtney Houchen, MD

    University of Oklahoma

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 17, 2012

First Posted

April 18, 2012

Study Start

October 1, 2010

Primary Completion

July 1, 2015

Study Completion (Estimated)

December 1, 2027

Last Updated

April 1, 2026

Record last verified: 2026-03

Locations

US(1)